RARE240719P40000
- 2.30
- 0.000.00%
Ultragenyx Pharmaceutical Newsroom
Ultragenyx Pharmaceutical(RARE.US) Director Sells US$23,932.32 in Common Stock
$Ultragenyx Pharmaceutical(RARE.US)$ Director Sanders Corazon (Corsee) D. sold 584 shares of common stock on Jul 2, 2024 at an average price of $40.98 for a total value of $23,932.32.Source: Announcem
'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News
'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare
Piper Sandler Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $135
Piper Sandler analyst Christopher Raymond maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and maintains the target price at $135.According to TipRanks data, the analyst has a success
TD Cowen Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $61
TD Cowen analyst Yaron Werber maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and maintains the target price at $61.According to TipRanks data, the analyst has a success rate of 54.0
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results.AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for
Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating
Ultragenyx Pharmaceutical (RARE) has an average rating of buy and price targets ranging from $45 to $140, according to analysts polled by Capital IQ. Price: 39.15, Change: -3.97, Percent Change: -9.22
Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday
Health care stocks were leaning lower pre-bell Friday with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) recently declining by 0.3% Cabaletta Bio (CABA) was over 4%
CCORF Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $111
CCORF analyst Whitney Ijem maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and maintains the target price at $111.According to TipRanks data, the analyst has a success rate of 50.0%
Express News | Ultragenyx Pharmaceutical Shares Down 2.8% Premarket After Co Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Ultragenyx Pharmaceutical Prices $350 Million Securities Offering
Jefferies Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $129
Jefferies analyst Maury Raycroft maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and maintains the target price at $129.According to TipRanks data, the analyst has a success rate of
Express News | Ultragenyx Pharmaceutical - Offering Pre-Funded Warrants to Purchase 1.5 Mln Shares of Its Common Stock at a Price of $38.999 per Pre-Funded Warrant
Ultragenyx Offering Expected to Close Around June 17 >RARE
Ultragenyx Offering Expected to Close Around June 17 >RARE
Ultragenyx: Gross Proceeds Expected at $350M >RARE
Ultragenyx: Gross Proceeds Expected at $350M >RARE
Express News | Ultragenyx Pharmaceutical Inc - Pricing of Its Public Offering of 7.4 Mln Shares of Its Common Stock at a Price of $39.00 per Share
Express News | Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Calendar Of Equity Issues Expected To Price This Week
Initial Offerings: Sound Point Meridian Capital Inc. (SPMC)--3.75 million shares expected to price Thursday via Oppenheimer & Co Inc, B Riley Securities Inc, Janney Mo
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $94 to $129
On Jun 13, major Wall Street analysts update their ratings for $Ultragenyx Pharmaceutical(RARE.US)$, with price targets ranging from $94 to $129.J.P. Morgan analyst Anupam Rama maintains with a buy ra
Ultragenyx Shares Slip Premarket on Planned Stock Offering
By Colin Kellaher Shares of Ultragenyx Pharmaceutical fell more than 10% in premarket trading Thursday after the biopharmaceutical company said it was raising up to $350 million in a public offering